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Abstract
Background
Selective cyclooxygenase-2 (COX-2) inhibitors are analgesic, antipyretic, and anti-inflam-
matory drugs. They have been found to inhibit the development of glioma in laboratory
investigations. Whether these drugs reduce the risk of glioma incidence in humans is
unknown.
Methods
We conducted a matched case-control analysis using the U.K.-based Clinical Practice
Research Datalink (CPRD). We identified 2,469 cases matched to 24,690 controls on age,
sex, calendar time, general practice, and number of years of active history in the CPRD
prior to the index date. We conducted conditional logistic regression analyses to determine
relative risks, estimated as odds ratios (ORs) with 95% confidence intervals (CIs) of glioma
in relation to use of selective COX-2 inhibitors, adjusted for several confounding variables.
Results
Use of selective COX-2 inhibitors was unrelated to risk of glioma (adjusted OR for 1–9 ver-
sus 0 prescriptions = 1.02; 95% CI = 0.92–1.13, 10–29 versus 0 prescriptions = 1.01; 95%
CI = 0.80–1.28,30 versus 0 prescriptions = 1.16; 95% CI = 0.86–1.55). Trends for increas-
ing numbers of prescriptions for other non-steroidal anti-inflammatory drugs (NSAIDs), and
non-NSAID analgesics were also not associated with glioma risk.
Conclusion
Further epidemiologic studies are needed to confirm the null relation of use of selective
COX-2 inhibitors to glioma risk and to explain the discrepancy between laboratory investiga-
tions and our observational study. Impact: Use of selective COX-2 inhibitors is unrelated to
glioma risk.
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Introduction
Malignant gliomas are highly aggressive tumours of the central nervous system [1]. Glioblas-
toma is the most common and malignant type of glioma and it is associated with a median
overall survival of 15 months despite aggressive therapy [1]. In contrast to many other cancers,
there are only a few established risk factors for gliomas including increasing age, male gender,
Caucasian ethnicity, rare genetic syndromes, and a high-level of ionizing radiation [2].
Selective COX-2 inhibitors are commonly used analgesics frequently prescribed for rheuma-
toid arthritis, dysmenorrhoea, or acute pain. Besides their analgesic, anti-inflammatory, and
antipyretic effects, they have been found to inhibit or kill glioma cells [3–9], increase radio-sen-
sitivity [10–15], reduce angiogenesis [14, 16–19], and stimulate anti-tumour immune reactions
in vitro and in established animal models [16, 20–23]. Clinical trials have tested selective COX-
2 inhibitors as adjuvant therapy for glioma, but results have been inconclusive thus far [17, 24–
32].
Although selective COX-2 inhibitors reduce gliomagenesis in vitro and in vivo [33], the
association between these agents and the risk of glioma has not yet been investigated in obser-
vational studies. Prior studies on NSAIDS and glioma, including one study using CPRD data
[34], reported null [34–38], inverse [39–42], or positive [43, 44] associations, but those studies
did not examine the effect of selective COX-2 inhibitors specifically. The lack of studies on the
effect of selective COX-2 inhibitors as a distinct group and the promising biological evidence
therefore prompted us to analyse the relation of selective COX-2 inhibitors use to the risk of
glioma.
Patients and Methods
Data source
The Clinical Practice Research Datalink (CPRD) is a primary care database that holds patient
information from around 600 general practices representative of the U.K. population with
respect to age, sex, and geographic distribution. Standard coding systems are used by general
practitioners to record data on patient diagnoses, prescriptions, hospital admissions, and refer-
rals to specialists. Data from office computers are transferred to electronic patient records, as
has been described previously [45]. The reliability of diagnostic coding in the CPRD database
has been thoroughly validated [46, 47].
The current study was approved by the Independent Scientific Advisory Committee of the
CPRD (protocol-number: 15_170). Patient records/information was anonymized and de-iden-
tified prior to analysis.
Study population
Case definition. We identified patients with newly diagnosed glioma between 1995 and
2015 using READ codes that are based on the WHO classification of glioma [48] as previously
described [49]. To validate glioma diagnoses, we used supporting codes such as codes for pro-
cedures, radio- or chemotherapy, and referrals to oncology clinics. Only patients younger than
90 years of age were included in the study population. The ‘index date’ was defined as the date
of the first glioma diagnosis minus one year. We shifted the date of diagnosis back by one year
for cases and controls to account for the lag time between disease development and detection/
diagnosis, to account for possible changes in medication use prior to the detection and diagno-
sis date of glioma, to control for changes in analgesic treatment, and to account for potential
earlier detection of pre-existing concomitant diseases in case patients caused by early symp-
toms of undiagnosed glioma. In order to increase the likelihood of capturing incident cases
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only and to ensure a sufficient history of medication exposure, we required all patients to have
an active history in the database for at least three years prior to the index date. We excluded
patients with a history of other concurrent cancers except non-melanoma skin cancer as well
as patients with recorded alcoholism or human immunodeficiency virus infection prior to the
index date.
Control definition. For each case, we identified at random up to 10 controls without a his-
tory of glioma from the CPRD base population matched on calendar time (same index date),
age (same year of birth +/- 3 years), sex, general practice, and number of years of active history
in the database prior to the index date. We assigned for each control the index date of the cor-
responding matching case. To minimize the risk of using control patients with a possible unre-
corded glioma diagnosis, we excluded control patients with a prior history of craniotomy
within the last year before the index date. Using a one-year time window was considered suffi-
cient due to the highly invasive phenotype of malignant glioma. We applied the same exclusion
criteria to controls as to cases.
Exposures
We assessed the use of selective COX-2 inhibitors (including etodolac (200–1000 mg/day),
meloxicam (7.5–15 mg/day), celecoxib (200–400 mg/day), rofecoxib (12.5–25 mg/day), etori-
coxib (30–120 mg/day), valdecoxib (10–40 mg/day), lumiracoxib (100–400 mg/day) and diclo-
fenac (50–150 mg/day)) from the computerized records. COX-2 selectivity can be determined
by dividing 50% inhibitory concentrations (IC50) of COX-2 by IC50 concentrations of COX-1
[50, 51]. Valdecoxib possesses the highest COX-2 selectivity (0.009 [50]), followed by etodolac
(0.021[50]), rofecoxib (0.029 [50]), meloxicam (0.032 [50]), celecoxib (0.036 [50]), etoricoxib
(0.032 [50]), diclofenac (0.1 [50]), ibuprofen (2.89 [50]), naproxen (>10.87 [50]), and aspirin
(>100 [51]). We categorized exposure to selective COX-2 inhibitors based on the number of pre-
scriptions prior to the index date. We categorized subjects who did not receive any selective
COX-2 drug prior to the index date as ‘no prior use’ (0 prescriptions, reference). Selective COX-2
users were classified into categories of 1–9, 10–29, or 30 prescriptions prior to the index date.
The number of prescriptions serves as an approximation of exposure duration, since an average
prescription covers 45 to 90 days of treatment, depending on the number of tablets (1 or 2) taken
per day. In a sensitivity analysis, we considered patients with< 5 prescriptions of selective COX-
2 inhibitors as non-users. We also investigated individual use of etodolac, meloxicam, celecoxib,
rofecoxib, etoricoxib, valdecoxib, lumiracoxib and diclofenac employing the same exposure cate-
gories as for the combined selective COX-2 inhibitor variable where possible.
Statistical analysis
We conducted conditional logistic regression analyses using the SAS statistical software version
9.4 (SAS Institute Inc, Cary, NC) to determine relative risks, estimated as odds ratios (ORs)
with 95% confidence intervals (CIs), of glioma in relation to use of selective COX-2 inhibitors.
A two-sided p-value of<0.05 was considered statistically significant. We performed tests of
linear trend by modelling the median value of each category as a continuous variable in the
multivariate model, the coefficient for which was evaluated using a Wald test.
In univariate analyses, we investigated the influence of various potential confounding vari-
ables, including body mass index (BMI,<18.5 kg/m², 18.5–24.9 kg/m², 25.0–29.9 kg/m²,30.0
kg/m², unknown), smoking status (never, current, past, unknown) and presence versus absence
of specific medical conditions or diseases (congestive heart failure, diabetes, rheumatoid arthri-
tis, allergies (asthma and hay fever), and use of estrogens (0, 1–14,15 prescriptions; women
only). We only included variables in the final multivariate analysis that altered the risk estimate
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of glioma by>10%. We adjusted our final analysis for BMI, smoking, diabetes, and congestive
heart failure. We also included other NSAIDs (ibuprofen, naproxen, and aspirin) and non-
NSAID analgesics (paracetamol, opioids) in the multivariate model. We stratified analyses by
gender and presence of supporting READ codes (surgery, chemotherapy, radiotherapy, or
referrals to a specialized oncology clinic). In further subanalyses, we restricted cases to glioblas-
toma patients, used the combination of all NSAIDs as exposure variable, excluded diclofenac
from the group of selective COX-2 inhibitors due to its lower affinity to COX-2, and investi-
gated mutually exclusive use of selective COX-2 inhibitors (i.e., excluding patients using other
NSAIDs from the study population).
Results
We identified 2,469 cases and 24,690 controls in the CPRD database. The mean age ± standard
deviation (SD) at the time of glioma diagnosis was 55.3 ± 18.8 years. 44.7% of cases and con-
trols were women. The mean number of years of active history in the database prior to the
index date was 11.3 ± 5.2 years for cases and controls. Among patients with knownWHO
grade of glioma (58.1%), 1,079 patients (75.2%) were diagnosed as glioblastoma.
Table 1 displays characteristics of glioma cases and controls. As with prior data using the
CPRD [49], underweight versus normal weight (OR = 0.42; 95% CI = 0.24–0.74), a history of
congestive heart failure (OR = 0.58; 95% CI = 0.38–0.87) and a history of diabetes mellitus
(OR = 0.81; 95% CI = 0.67–0.97) were related to reduced glioma risk. Current versus never
smoking (OR = 0.87; 95% CI = 0.77–0.99) also showed an inverse relation to glioma. By com-
parison, no associations with glioma were found for rheumatoid arthritis, history of allergies,
or use of estrogens in women.
Table 2 provides ORs of glioma in association with use of selective COX-2 inhibitors or use
of other NSAIDs or non-NSAID analgesics. There was no association between use of selective
COX-2 inhibitors and risk of glioma. As compared with no prior use, the OR for 1–9 prescrip-
tions was 1.02 (95% CI = 0.92–1.13), for 10–29 prescriptions it was 1.01 (95% CI = 0.80–1.28),
and for30 prescriptions it was 1.16 (95% CI = 0.86–1.55, p-value for trend = 0.408). Results
were similar for aspirin and ibuprofen (Table 2).
We noted that as compared with no prior use, 10–29 prescriptions of naproxen or 1–9 pre-
scriptions of paracetamol were inversely associated with glioma risk (OR = 0.52; 95%
CI = 0.28–0.96, OR = 0.80; 95% CI = 0.68–0.94, respectively), but there was no significant
trend with increasing numbers of prescriptions (naproxen: p-value for trend = 0.692; paraceta-
mol: p-value for trend = 0.403). Use of 1–9 prescriptions of opiates/opioids was positively asso-
ciated with glioma risk (OR = 1.32; 95% CI = 1.12–1.56) but again, there was no detectable
dose-response relation when investigating increasing duration of drug use (p-value for
trend = 0.439) (Table 2). When analysing individual selective COX-2 inhibitors in relation to
glioma risk, we found no significant associations with use of etodolac, meloxicam, celecoxib,
rofecoxib, etoricoxib, valdecoxib, lumiracoxib, or diclofenac (Table 3). Frequencies of use of
the specific COX-2 inhibiting drugs and the grouped variable of “selective COX-2 inhibitors”
vary due to successive or combined use of several selective COX-2 inhibitors.
There was no effect modification by sex or when restricting cases (and corresponding con-
trols) to glioblastoma patients or to glioma patients with READ codes for surgery, chemother-
apy, radiotherapy, or referrals to a specialized oncology clinic. The results remained similar to
those of our main analysis when we conducted analyses of patients with<5 prescriptions of
selective COX-2 inhibitors as the non-exposed, when combining all NSAIDs, when excluding
diclofenac from the group of selective COX2 inhibitors, or when investigating mutually exclu-
sive use of selective COX-2 inhibitors (data not shown).
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Discussion
To the best of our knowledge, the current analysis is the first observational study to report on
use of selective COX-2 inhibitors specifically in relation to the risk of glioma. In contrast to a
large number of laboratory studies showing potential preventive effects of selective COX-2
inhibitors on glioma pathogenesis, we found no association between selective COX-2 inhibitor
use and glioma.
The relation of NSAID use to risk of glioma or brain cancer has been explored in a number
of previous observational studies. Three case–control studies observed a statistically significant
Table 1. Characteristics of glioma cases and controls.
Variable Number of cases (%) (n = 2,469) Number of controls (%) (n = 24,690) OR (95% CI)*
Age (years)*
0–9 72 (2.9) 728 (3.0) -
10–19 95 (3.9) 941 (3.8) -
20–29 113 (4.6) 1,122 (4.5) -
30–39 182 (7.4) 1,827 (7.4) -
40–49 273 (11.1) 2,765 (11.2) -
50–59 536 (21.7) 5,308 (21.5) -
60–69 608 (24.6) 6,151 (24.9) -
70–79 450 (18.2) 4,514 (18.3) -
80–90 140 (5.7) 1,334 (5.4) -
Sex*
Men 1,365 (55.3) 13,650 (55.3) -
Women 1,104 (44.7) 11,040 (44.7) -
BMI (kg/m2)
< 18.5 13 (0.5) 289 (1.2) 0.42 (0.24–0.74)
18.5–24.9 753 (30.5) 7,119 (28.8) 1.00 (reference)
25–29.9 749 (30.3) 7,295 (29.6) 0.97 (0.87–1.08)
30.0 401 (16.2) 4,046 (16.4) 0.94 (0.83–1.07)
Unknown 553 (22.4) 5,941 (24.1) 0.84 (0.73–0.96)
Smoking status
Never smoker 1,185 (48.0) 11,071 (44.8) 1.00 (reference)
Current smoker 398 (16.1) 4,220 (17.1) 0.87 (0.77–0.99)
Past smoker 578 (23.4) 5,784 (23.4) 0.94 (0.84–1.05)
Unknown 308 (12.5) 3,615 (14.6) 0.69 (0.58–0.82)
Comorbidities
CHF 25 (1.0) 424 (1.7) 0.58 (0.38–0.87)
Diabetes 138 (5.6) 1,674 (6.8) 0.81 (0.67–0.97)
Rheumatoid arthritis 24 (1.0) 277 (1.1) 0.86 (0.57–1.32)
Allergies 89 (3.6) 944 (3.8) 0.94 (0.75–1.18)
Medication use
Estrogens#
No prior use 837 (75.8) 8,340 (75.5) 1.00 (reference)
1–14 Rx 177 (16.0) 1,812 (16.4) 1.03 (0.86–1.25)
 15 Rx 90 (8.2) 888 (8.0) 1.04 (0.79–1.36)
*Matching variables: age, sex, general practice, and number of years of active history in the database.
#Women only. BMI: Body mass index; CHF: congestive heart failure; OR: Odds ratio, Rx: prescriptions.
doi:10.1371/journal.pone.0149293.t001
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inverse association between use of NSAIDs and risk of glioma [40, 41] or glioblastoma [39]
Three other case-control studies [34, 38, 42], one prospective cohort study [37], one random-
ized clinical trial [36], and one recent meta-analysis [35] found no association between NSAID
use and brain tumour risk, and two previous cohort studies [43, 44] found an increased risk of
brain tumours among NSAID users. Such heterogeneity of results from previous studies may
Table 2. Risk of glioma in patients using NSAIDs or other analgesics.
Variable Number of cases (%) (n = 2,469) Number of controls (%) (n = 24,690) Adjusted OR (95% CI)*/#
Selective COX-2 inhibitors
No prior use 1,609 (65.2) 16,242 (65.8) 1.00 (reference)
1–9 Rx 710 (28.8) 6,982 (28.3) 1.02 (0.92–1.13)
10–29 Rx 91 (3.7) 939 (3.8) 1.01 (0.80–1.28)
 30 Rx 59 (2.4) 527 (2.1) 1.16 (0.86–1.55)
p-value for trend 0.408
Aspirin
No prior use 2,405 (97.4) 23,954 (97.0) 1.00 (reference)
1–9 Rx 40 (1.6) 481 (2.0) 0.83 (0.60–1.15)
10–29 Rx 11 (0.5) 140 (0.6) 0.80 (0.43–1.50)
 30 Rx 13 (0.5) 115 (0.5) 1.19 (0.66–2.13)
p-value for trend 0.748
Ibuprofen
No prior use 1,676 (67,9) 16,607 (67,3) 1.00 (reference)
1–9 Rx 718 (29.1) 7,353 (29.8) 0.95 (0.86–1.05)
10–29 Rx 53 (2.2) 505 (2.1) 1.03 (0.77–1.39)
 30 Rx 22 (0.9) 225 (0.9) 0.94 (0.60–1.48)
p-value for trend 0.932
Naproxen
No prior use 2,166 (87.7) 21,454 (86.9) 1.00 (reference)
1–9 Rx 277 (11.2) 2,931 (11.9) 0.91 (0.79–1.05)
10–29 Rx 11 (0.5) 203 (0.8) 0.52 (0.28–0.96)
 30 Rx 15 (0.6) 102 (0.4) 1.45 (0.83–2.52)
p-value for trend 0.692
Non-NSAID analgesics
Paracetamol
No prior use 1,291 (52.3) 12,839 (52.0) 1.00 (reference)
1–9 Rx 841 (34.1) 8,417 (34.1) 0.80 (0.68–0.94)
10–29 Rx 168 (6.8) 1,674 (6.8) 0.87 (0.66–1.14)
 30 Rx 169 (6.8) 1,760 (7.1) 0.76 (0.55–1.06)
p-value for trend 0.403
Opioids
No prior use 1,319 (53.4) 13,556 (54.9) 1.00 (reference)
1–9 Rx 853 (34.6) 8,106 (32.8) 1.32 (1.12–1.56)
10–29 Rx 135 (5.5) 1,405 (5,7) 1.19 (0.88–1.60)
 30 Rx 162 (6.6) 1,623 (6.6) 1.35 (0.96–1.89)
p-value for trend 0.439
*Matching variables: age, sex, general practice, and number of years of active history in the database. #Adjustment for body mass index, smoking,
diabetes, congestive heart failure, and all other medications in this table. COX: Cyclooxygenase; NSAIDs: non-steroidal anti-inﬂammatory drugs; Rx:
prescriptions.
doi:10.1371/journal.pone.0149293.t002
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be due to differences in study designs, exposure assessments (i.e., self-reported versus medical
record data), underlying drug dosages, durations of use, and adjustments for covariates [35].
Table 3. Risk of glioma in patients using etodoloac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib, lumiracoxib or diclofenac.
Variable Number of cases (%) (n = 2,469) Number of controls (%) (n = 24,690) Adjusted OR (95% CI)*/#
Etodolac
No prior use 2,441 (98.9) 24,477 (99.1) 1.00 (reference)
1–9 Rx 21 (0.9) 180 (0.7) 0.79 (0.17–3.70)
10–29 Rx 5 (0.2) 20 (0.1) 1.77 (0.30–10.42)
 30 Rx 2 (0.1) 13 (0.1) 0.64 (0.15–2.81)
p-value for trend 0.260
Meloxicam
No prior use 2,399 (97.2) 24,006 (97.2) 1.00 (reference)
1–9 Rx 55 (2.2) 565 (2.3) 0.98 (0.73–1.31)
10–29 Rx 11 (0.5) 77 (0.3) 1.37 (0.71–2.66)
 30 Rx 4 (0.2) 42 (0.2) 0.98 (0.34–2.82)
p-value for trend 0.662
Celecoxib
No prior use 2,395 (97.0) 23,983 (97.1) 1.00 (reference)
1–9 Rx 60 (2.4) 613 (2.5) 1.00 (0.75–1.33)
10–29 Rx 10 (0.4) 71 (0.3) 1.51 (0.76–3.00)
 30 Rx 4 (0.2) 23 (0.1) 1.67 (0.57–4.89)
p-value for trend 0.196
Rofecoxib
No prior use 2,407 (97.5) 24,051 (97.4) 1.00 (reference)
1–9 Rx 52 (2.1) 530 (2.2) 0.99 (0.73–1.33)
10–29 Rx 9 (0.4) 88 (0.4) 0.92 (0.45–1.88)
 30 Rx 1 (0.0) 21 (0.1) 0.61 (0.10–3.63)
p-value for trend 0.473
Etoricoxib
No prior use 2,441 (98.9) 24,424 (98.9) 1.00 (reference)
1–9 Rx 26 (1.1) 223 (0.9) 1.12 (0.73–1.71)
 10 Rx 2 (0.1) 43 (0.2) 0.50 (0.12–2.05)
p-value for trend 0.263
Valdecoxib
No prior use 2,467 (99.9) 24,663 (99.9) 1.00 (reference)
 1 Rx 2 (0.1) 27 (0.1) 0.80 (0.19–3.36)
Lumiracoxib
No prior use 2,468 (100.0) 24,684 (100.0) 1.00 (reference)
 1 Rx 1 (0.0) 6 (0.0) 1.28 (0.10–16.42)
Diclofenac
No prior use 1,683 (68,2) 16,902 (68,5) 1.00 (reference)
1–9 Rx 676 (27.4) 6,733 (27.3) 1.00 (0.90–1.11)
10–29 Rx 70 (2.8) 690 (2.8) 1.05 (0.81–1.36)
 30 Rx 40 (1,6) 365 (1.5) 1.09 (0.77–1.54)
p-value for trend 0.539
*Matching variables: age, sex, general practice, and number of years of active history in the database. #Adjustment for body mass index, smoking,
diabetes, congestive heart failure, all other medications in this table and Table 2 except the combined variable of selective COX-2 inhibitors.
doi:10.1371/journal.pone.0149293.t003
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None of the aforementioned studies [34–44] investigated the association between use of
selective COX-2 inhibitors specifically and glioma risk. A large number of laboratory investiga-
tions reported on inhibitory effects of selective COX-2 inhibitors on various stages of glioma
pathogenesis [3–6, 8–13, 15, 18–23], prompting clinical trials to investigate selective COX-2
inhibitors as adjuvant therapy for glioma [24–32]. The discrepancy between the laboratory
findings and our results may be explained by a number of factors. First, despite mechanistic
data regarding protective effects of selective COX-2 inhibitors on glioma development [33],
most preclinical studies were designed to investigate therapeutic rather than preventive drug
effects. In addition, drug doses used in in vitro experiments often exceeded the usual drug con-
centrations reached in the brain, particularly in experiments involving intratumoral applica-
tion of selective COX-2 inhibitors or coupling of selective COX-2 inhibitors to nanoparticles
aimed at increasing drug concentrations in the tumour [52]. Phase I/II clinical trials were also
unable to show a clear benefit of adjuvant therapy with selective COX-2 inhibitors [24, 25, 28–
31], even though they were modelled on biological tumour models and used combined thera-
peutic approaches.
Our null result for selective COX-2 inhibitors and glioma are in line with previous null
results for glioma and use of diclofenac, which has a 4-fold higher selectivity for COX-2 than
COX-1 [51].
We observed an increased glioma risk in association with short-term use of opiates/opioids.
Possible underlying biologic mechanisms remain speculative but may involve opiate-mediated
activation of Mitogen-Activated-Kinases [53] or Akt kinases [54]. However, confounding by
indication due to opiate or selective COX-2 inhibitors use in patients with pre-existing but
undiagnosed glioma or glioblastoma is another possible explanation, despite the fact that we
shifted the index date backward in time by one year for cases and controls.
Certain shortcomings of our study warrant discussion. While patients using selective COX-
2 inhibitors require drug prescriptions, other NSAIDs such as aspirin, ibuprofen, and naproxen
are available over the counter (OTC) in the UK [55]. We therefore may have underestimated
NSAID use in patients taking OTC medications, which could have biased the risk estimates
towards the null value. However, a prior study showed that prescription-based data adequately
reflect use of OTC medications [56]. Also, we had rather small sample sizes in some exposure
categories, such as long-term intake of selective COX-2 inhibitors among cases. We were
unable to closely control for socioeconomic status, and we were not able to take physical activ-
ity or other lifestyle factors possibly related to glioma into account in our analyses, because
these variables are not regularly recorded in the CPRD. However, prior studies have not
revealed meaningful associations between adulthood lifestyle factors and glioma risk [57, 58].
Our findings may not apply to non-Caucasian populations, because 86% of individuals in our
database are Caucasian [59].
Our study has a number of important strengths. The CPRD is a well-established, large-, and
validated database [46]. Because we generated cases and controls from a pre-existing database,
selection bias is unlikely. Further, recall bias is absent because the data regarding medications
and concomitant diseases were collected prospectively. Finally, only patients with an active his-
tory of at least three years in the CPRD database were included in the current study in order to
increase the likelihood of capturing only newly diagnosed cases and to ensure a sufficiently
long history of exposure to selective COX-2 inhibitor use.
In summary, we found no association between use of selective COX-2 inhibitors and the
risk of glioma. Further observational studies are warranted to confirm our findings and to help
explain the apparent discrepancies between laboratory and observational data.
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